Singapore markets close in 1 hour 34 minutes
Straits Times Index
3,278.93 -9.02 (-0.27%) Nikkei
28,257.25 -76.27 (-0.27%) Hang Seng
24,066.44 -151.59 (-0.63%) FTSE 100
7,611.23 +68.28 (+0.91%) BTC-USD
42,153.72 -681.44 (-1.59%) CMC Crypto 200
1,011.90 -13.83 (-1.35%)
Revance Therapeutics, Inc. (RVNC)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 15.05 |
| Open | 14.89 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1100 |
| Day's range | 14.80 - 15.44 |
| 52-week range | 12.34 - 33.83 |
| Volume | |
| Avg. volume | 982,391 |
| Market cap | 1.103B |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.47 |
| Earnings date | 21 Feb 2022 - 25 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 28.11 |
- Business Wire
Revance Provides Preliminary Fourth Quarter and Full Year 2021 Financial Results and a Corporate Update
NASHVILLE, Tenn., January 07, 2022--Revance Provides Preliminary Fourth Quarter and Full Year 2021 Financial Results and a Corporate Update
- Business Wire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC)
LOS ANGELES, December 21, 2021--Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming February 8, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) securities between November 25, 2019 and October 11, 2021, inclusive (the "Class Period").
- Business Wire
RVNC Shareholders: Robbins LLP Reminds Investors of Class Action Against Revance Therapeutics, Inc. (RVNC)
SAN DIEGO, December 21, 2021--Revance Therapeutics, Inc. (RVNC) Misled Investors Regarding FDA Approval of its Lead Drug Candidate
© 2022 Yahoo. All rights reserved.
